These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32248654)

  • 1. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
    Urick ME; Bell DW
    Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
    Urick ME; Bell DW
    Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels.
    Urick ME; Yu EJ; Bell DW
    Cancer; 2021 Aug; 127(16):2905-2915. PubMed ID: 33872388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
    Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
    J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
    Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
    BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
    Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH
    Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
    Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of tumor suppressors changes the endometrial tumor spectrum.
    Mayo LD
    EMBO Mol Med; 2023 Oct; 15(10):e18166. PubMed ID: 37587857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In search for biomarkers and potential drug targets for uterine serous endometrial cancer.
    Dinoi G; Mariani A; Martinelli E; Ciucci A; Zannoni GF; Weaver AL; Keeney GL; Vasmatzis G; Anastasiadis PZ; Fanfani F; Scambia G; Gallo D
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1647-1658. PubMed ID: 33754208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STYX/FBXW7 axis participates in the development of endometrial cancer cell via Notch-mTOR signaling pathway.
    Liu L; Jiang H; Wang X; Wang X; Zou L
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.
    Jamieson A; Sobral de Barros J; Cochrane DR; Douglas JM; Shankar S; Lynch BJ; Leung S; Martin S; Senz J; Lum A; Drew Y; Gilks CB; Huntsman DG; McAlpine JN
    Clin Cancer Res; 2024 Jun; 30(11):2461-2474. PubMed ID: 38536067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs.
    Devor EJ; Hovey AM; Goodheart MJ; Ramachandran S; Leslie KK
    Oncol Rep; 2011 Oct; 26(4):995-1002. PubMed ID: 21725615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis.
    Brown M; Leon A; Kedzierska K; Moore C; Belnoue-Davis HL; Flach S; Lydon JP; DeMayo FJ; Lewis A; Bosse T; Tomlinson I; Church DN
    EMBO Mol Med; 2023 Oct; 15(10):e17094. PubMed ID: 37589076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Thyroid Receptor Interacting Protein 6 by MicroRNA-589-5p Inhibits Cell Proliferation, Migration, and Invasion in Endometrial Carcinoma.
    Wang Y; Dong L; Liu Y
    Cancer Biother Radiopharm; 2019 Oct; 34(8):529-536. PubMed ID: 31424277
    [No Abstract]   [Full Text] [Related]  

  • 15.
    Xu Z; Zhuang L; Wang X; Li Q; Sang Y; Xu J
    Future Oncol; 2020 Sep; 16(25):1921-1930. PubMed ID: 32915667
    [No Abstract]   [Full Text] [Related]  

  • 16. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
    Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
    Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
    Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
    Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uterine superficial serous carcinomas and extensive serous endometrial intraepithelial carcinomas: clinicopathological analysis of 6 patients.
    Ono K; Hayashi H; Tateno M; Tanaka R; Suzuki R; Maruyama Y; Miyagi Y; Furuya M
    Int J Clin Exp Pathol; 2014; 7(11):7979-88. PubMed ID: 25550841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
    Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
    Gonzalez-Bosquet J; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Couch FJ; Podratz KC
    Gynecol Oncol; 2021 Jul; 162(1):182-189. PubMed ID: 33867147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.